Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis

Alan H. Bryce, Rhett P. Ketterling, Morie A. Gertz, Martha Lacy, Ryan A. Knudson, Steven Zeldenrust, Shaji Kumar, Suzanne Hayman, Francis Buadi, Robert A. Kyle, Philip R. Greipp, John A. Lust, Stephen Russell, S. Vincent Rajkumar, Rafael Fonseca, Angela Dispenzieri

Research output: Contribution to journalArticle

65 Scopus citations

Abstract

Background Light chain amyloidosis is a rare plasma cell dyscrasia. Interphase fluorescence in situ hybridization (FISH) coupled to cytoplasmic staining of specific Ig (clg-FISH) on bone marrow plasma cells has become well established in the initial evaluation of multiple myeloma, a related disorder. Little, however, is known about cytogenetic abnormalities in patients with light chain amyloidosis. Design and Methods We reviewed 56 patients with light chain amyloidosis who had clg-FISH performed as part of their routine clinical testing using the standard screening panel employed in multiple myeloma at our institution. Results Seventy percent of patients had abnormal clg-FISH, with the most common abnormalities being IgH translocations [48%] - including t(ll;14) [39%], and t(14;16) [2%] - and dell3/dell3q [30%]. No t(4;14) or deletions of 17p (p53) were observed. Patients with t(ll;14) had the lowest levels of clonal plasma cells, and those with dell3 had the highest. The risk of death for patients harboring the t(ll;14) translocation was 2.1 (CI 1.04-6.4), which on multivariate analysis was independent of therapy. Conclusions Although preliminary, our data would suggest that clg-FISH testing is important in patients with light chain amyloidosis and that t(ll;14) is an adverse prognostic factor in these patients.

Original languageEnglish (US)
Pages (from-to)380-386
Number of pages7
JournalHaematologica
Volume94
Issue number3
DOIs
StatePublished - Mar 1 2009

    Fingerprint

Keywords

  • Amyloidosis
  • Clg-fish
  • T(11;14)

ASJC Scopus subject areas

  • Hematology

Cite this